ALS siden
Up

Du er besøkende nr.(You're visitor no). siden 23. des.1998 (since Dec.23. 1998)

red_arrow.gif (871 bytes) Sist oppdatert 5/3/2004

Fordi den nevrologiske forskningen på ALS ofte har interesse også for slag, og jeg derfor har hatt interessant kontakt med med noen som er rammet av ALS, laget jeg i sin tid denne ALS-siden, men har dessverre ikke hatt tid til å følge opp ALS-forskningen spesielt. Så, om det finnes noen, som ønsker å hjelpe til med å redigere denne siden, ville jeg være takknemlig!

Trond Ruud

Skandinaviske ALS-kontaktsider på Internet:

ALS  FORUM

 

red_arrow.gif (871 bytes) ÅSES HJEMMESIDE Norsk Hjemmeside om ALS

Andre linker

  1. Can transplanted stem cells restore function and increase survival?
    Dr. Ole Isacson, Director of the Neuroregeneration Laboratories and Morris K. Udall Parkinson's Disease Research Center of Excellence at the McLean Hospital, will apply his expertise in transplant studies in Parkinson's disease to investigate whether stem cell transplants into a rat model of ALS will restore function and increase survival. Genetically modified embryonic stem cells (HB9 GFP ES cells) will be provided by Dr. Tom Jessell. (This work has recently been published in the journal Cell.) Research in Dr. Tom Jessell's laboratory has demonstrated that these mouse embryonic stem cells can be differentiated into motor neurons (the population of nerve cells that die in ALS)
    Can human motor neurons be generated from stem cells?

  2. Doctor's Guide om ALS (Lou Gehrig's Disease)  
    The latest medical news and information for patients or friends/parents of patients diagnosed with ALS

  1. The ALS Association  
    The ALS Association seeks to promote awareness and understanding of ALS and the work of The ALS Association by providing up-to-date information and education materials to the ALS community... ALS patients and families, caregivers, researchers and members in the health care fields. ALS (amyotrophic lateral sclerosis) is a fatal neurodegenerative disease. It is often called Lou Gehrig's disease.

  2. Harvard Neurology Web ALS Forum
    This is a webforum to discuss and comment on ALS

  3. Foreningen for Muskelsyke  (FFO)

  4. FDA Approval of the First Treatment for ALS - Orbis Radio News Special Report.

  5. Rhone-Poulenc Rorer, Inc. - New product approved by FDA to treat Lou Gehrig's Disease - Rilutek

  6. Drosophila Meets Lou Gehrig's Disease
    An article about using the fruit fly to study the disease.

  7. COMMONLY ASKED QUESTIONS ABOUT RILUTEK® (riluzole) Tablets

  1. The ALS Newsletter.

  2. Coenzyme Q10 Saves Nerve Cells in Mice with ALS

  3. Myotrophin Slows Progression Of Lou Gehrig's Disease

  4. Gene-Reading Problem Linked To Lou Gehrig's Disease

  5. Zanaflex® As A Treatment For Spasticity

  6. Brain Function Restored Because of Testes Cells Brain Function Restored Because of Testes Cells Ny! 13/3/99
    SOUTH SAN FRANCISCO, Calif., July 12, 1996 -- A new technology that involves implanting cells from the testes into the brain may help restore brain function in victims of Parkinson's disease, stroke, Lou Gehrig's disease, traumatic brain injury and other brain disorders

  7. Creatine Supplements Could Help Muscular Disease
    Creatine, a food supplement controversial because of its heavy use by some athletes, may work to help people with diseases such as muscular dystrophy, researchers said on Wednesday. Patients who took it had a small but significant improvement in muscle strength and ability to exercise, Dr. Mark Tarnopolsky of McMaster University Medical Centre in Hamilton, Ontario, said.
    (See Story from Fox News) (3/12/99)

  8. AVANIR (AVNR) To License Worldwide Rights For Drug To Treat ALS-Related Symptoms
    AVANIR Pharmaceuticals (Nasdaq: AVNR), announced today it has signed a letter of intent, subject to approval of a definitive agreement, with IriSys Research & Development, LLC to license the worldwide rights to a new drug to treat a condition associated with Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig's disease. The new drug is a patented combination of dextromethorphan and an enzyme inhibitor, for which the Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application. AVANIR expects to start Phase II clinical trials in the first half of 1999. Two other indications to be pursued include treatments of certain types of pain and chronic intractable cough.
    (See press release) (2/5/99)

  9. Brain Work
     ALS: apparently less settled than we thought.     The degenerative neuromuscular disease amyotrophic lateral sclerosis (ALS), which constrains the life of world-renowned physicist Stephen Hawking among others, received a great deal of attention several years ago, when it seemed that the genetic basis of this fatal disorder was at last becoming clear. But familial ALS may soon be in the limelight again, as a new study published in Science (Sept. 18) casts some doubt on the accepted explanation. The new study, headed by neuroscientist Don Cleveland at the University of California-San Diego, bred particular strains of mice to manipulate the offspring's production of an enzyme known as superoxide dismutase, or SOD1. (The previous thinking was that mutations in the genetic coding for SOD1 caused some individuals to produce less effective forms of SOD, which were unable to remove cell-damaging superoxide molecules). Starting from a mutant that retained little normal function, Cleveland and his colleagues found that disease onset and progression were not exacerbated by complete removal of the normal protein, nor were they relieved by increasing it. The scientists conclude that strategies to treat disease by drugs that increase SOD1 activity are very unlikely to be successful. Further, the evidence calls into question the initial idea that the toxic effects of the SOD1 mutants are related to oxidative damage from superoxide.